Myasthenia

New York, July 01, 2022 (GLOBE NEWSWIRE) -- According to one of the statistics published by the National Center for Biotechnology Information (NCBI), the prevalence rate for Myasthenia…

Pune, India, May 26, 2022 (GLOBE NEWSWIRE) -- The global myasthenia gravis treatment market size is anticipated to reach USD 2.03 billion by 2028 and exhibit a CAGR of 7.5% during the…

SEATTLE -- An agent that works similarly to the approved myasthenia gravis (MG) drug eculizumab (Soliris) but with a longer dosing…

Pune, India, Feb. 28, 2022 (GLOBE NEWSWIRE) -- The global myasthenia gravis treatment market size is anticipated to reach USD 2.03 billion by 2028 and exhibit a CAGR of 7.5% during the…

NEW YORK, Dec. 30, 2021 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune…

Efgartigimod (Vyvgart) was approved to treat generalized myasthenia gravis in adults who test…

Los Angeles, USA, July 22, 2021 (GLOBE NEWSWIRE) -- Recent Clinical Trials Analysis on Myasthenia Gravis Treatment   Around 15+ key companies are developing the Myasthenia Gravis…